<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2811211380
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KLARE 500 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        46.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Klare belongs to a group of medicine called macrolide antibiotics. Antibiotics stop the growth of bacteria<br />(bugs) which cause infections.<br />Klare tablets are used to treat following infections:<br />&bull; Chest infections such as bronchitis and pneumonia,<br />&bull; Throat and sinus infections,<br />&bull; Skin and soft tissue infections,<br />&bull; Helicobacter pylori infections associated with duodenal ulcers.<br />Klare tablets are indicated in adults and children 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Klare Tablets if you:<br />&bull; are allergic to clarithromycin or other macrolide antibiotics such as erythromycin or azithromycin, or any of<br />the other ingredients of Klare Tablets.<br />&bull; are taking medicines called ergotamine or dihydroergotamine tablets or use ergotamine inhalers for<br />migraine.<br />&bull; are taking medicines called terfenadine or astemizole (widely taken for hay fever or allergies) or cisapride<br />(for stomach disorders) or pimozide (for mental health problems) as combining these drugs can<br />sometimes cause serious disturbances in heart rhythm.<br />&bull; are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known as statins, used to<br />lower levels of cholesterol (a type of fat) in the blood).<br />&bull; have low levels of potassium in the blood (a condition known as hypokalaemia)<br />&bull; have an irregular heart rhythm<br />&bull; have severe liver disease with kidney disease.<br />Klare tablets are not suitable for use in children under 12 years of age.<br />Warnings and precautions:<br />&bull; you are pregnant or breast-feeding<br />&bull; you have, or are prone to, fungal infections (e.g. thrush)<br />&bull; you are suffering from liver or kidney problems<br />If any of these apply to you, consult your doctor before taking Klare tablets.<br />Other medicines and Klare tablets:<br />You should not take Klare tablets if you are taking any of the medicines listed in the section above &ldquo;Do not take<br />Klare tablets if you;&rdquo;<br />Tell your doctor if you are taking any of the following medicines as your dose may need to be changed or you<br />may need to have regular tests performed. Care is needed if you are taking<br />&bull; Digoxin, disopyramide or quinidine (used to treat heart conditions)<br />&bull; carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy)<br />&bull; atorvastatin, rosuvastatin (HMG-CoA reductase inhibitors, commonly known as statins, and used to lower<br />levels of cholesterol (a type of fat) in the blood). Statins can cause rhabdomyolosis (a condition which cause<br />the breakdown of muscle tissue which can result in kidney damage) and signs of myopathy (muscle pain or<br />muscle weakness) should be monitored.<br />&bull; theophylline (used in patients with breathing difficulties such as asthma)<br />&bull; triazolam, alprazolam or midazolam (sedatives)<br />&bull; Cilostazol (used to treat poor circulation)<br />&bull; Methylprednisolone (a corticosteroid)<br />&bull; Oral anticoagulants (e.g. warfarin, used to thin the blood)<br />&bull; Nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood glucose levels)<br />&bull; Sildenafil, vardenafil and tadalafil (used to treat impotence in adult males or to or for use in pulmonary<br />arterial hypertension (high blood pressure in the blood vessels of the lungs)<br />&bull; Vinblastine (used to treat cancer)<br />&bull; Omeprazole (for treatment of indigestion and gastric ulcers) unless your doctor has prescribed it for you to<br />treat Helicobacter pylori infection associated with duodenal ulcer<br />&bull; Ciclosporin, sirolimus or tacrolimus (immune suppressants )<br />&bull; etravirine, efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (anti-viral drugs used in the<br />treatment of HIV)<br />&bull; Rifampicin, rifapentine, fluconazole, itraconazole or rifabutin (used for treatment of certain bacterial<br />infections)<br />&bull; Tolterodine (for overactive bladder)<br />&bull; Verapamil, amlodipine, diltiazem (for high blood pressure).<br />&bull; St John&#39;s Wort (a herbal product used to treat depression).<br />&bull; Colchicine (usually taken for gout).<br />&bull; Aminoglycosides (a group of antibiotic to treat certain bacteria for example gentamicin, neomycin)<br />Klare does not interact with oral contraceptives.<br />Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines,<br />including those obtained without a prescription.<br />Taking Klare Tablets with food and drink Klare Tablets may be taken with or without food.<br />Pregnancy, breast-feeding and fertility<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your<br />doctor or pharmacist for advice before taking this medicine,as the safety of Klare tablets in pregnancy and<br />breast-feeding is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A. One tablet contain 500 mg.<br />B. Half a tablet contain 250 mg.<br />Note: to split tablet place it on a hard surface and press down with one thumb on the left of the dividing groove<br />and the other thumb on the right. The tablet can thus be readily split into halves.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>pharmacist if you are not sure.<br />Do not give these tablets to children under 12 years. Your doctor will prescribe another suitable medicine for<br />your child.<br />The dose of Klare varies with the condition being treated. The dose you should take will be on the<br />pharmacist&#39;s label. Always take the tablets exactly as your doctor has told you to. You should check<br />with your doctor or pharmacist if you are not sure.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />Klare tablets may make you feel dizzy or drowsy. If they affect you in this way do not drive, operate machinery<br />or do anything that requires you to be alert.<br />Klare Tablets should be swallowed with at least half a glass of water.<br />&bull; For treating chest infections, throat or sinus infections and skin and soft tissue infections:<br />Usual dose of klare for adults and children over 12 years is 250mg twice daily for 6 to 14 days, e.g.<br />250mg (Half tablet) in the morning and (Half tablet) in the early evening. Your doctor may increase the<br />dose to 500mg (One tablet) twice daily in severe infections<br />&bull; For treating Helicobacter pylori infections associated with duodenal ulcers: There are a number of<br />effective treatment combinations available to treat Helicobacter pylori in which klare tablets are taken<br />together with one or two other drugs. These combinations include the following and are usually taken for 6 to<br />14 days:<br />a) One Klare 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day plus<br />lansoprazole, 30 mg twice a day.<br />b) One Klare 500 mg tablet taken twice a day together with metronidazole, 400 mg taken twice a day plus<br />lansoprazole, 30 mg twice a day.<br />c) One Klare 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day or<br />metronidazole, 400 mg taken twice a day plus omeprazole, 40 mg a day.<br />d) One Klare 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day plus<br />omeprazole, 20 mg taken once a day.<br />e) One Klare 500 mg tablet taken three times a day together with omeprazole 40 mg taken once a day.<br />The treatment combination that you receive may differ slightly from the above. Your doctor will decide which<br />treatment combination is the most suitable for you. If you are unsure which tablets you should be taking or&nbsp;If you have any kidney problems your dose may be different from that given here, Do not change unless your<br />doctor tells you to do so.<br />Dosage in patients with renal impairment:<br />The maximum recommended dosages should be reduced proportionately to renal impairment. In patients<br />with renal impairment with creatinine clearance less than 30 mL/min, the dosage of Klare should be reduced<br />by one-half, i.e. 250 mg once daily (Half tablet), or 250 mg (Half tablet) twice daily in more severe infections.<br />Treatment should not be continued beyond 14 days in these patients.<br />If you take more Klare Tablets than you should<br />If you or someone else swallows several of these tablets all together, or you think a child has swallowed any of<br />these tablets, contact your doctor or pharmacist or hospital emergency department immediately. An overdose<br />of Klare tablets is likely to cause vomiting and stomach pains.<br />If you forget to take Klare tablets<br />If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, do not take the<br />missed dose and just carry on as before. Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Klare Tablets:<br />You must take your medicine for as long as your doctor has told you to. This will usually be for 6 to 14 days<br />depending on the type and severity of infection. It is important not to stop taking the medicine just because you<br />feel better as the infection could return.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If any of the following happen, stop taking Klare Tablets and tell your doctor immediately or go to<br />the casualty department at your nearest hospital:<br />&bull; severe or prolonged diarrhoea, which may have blood or mucus in it. Diarrhoea may occur over two months<br />after treatment with clarithromycin, in which case you should still contact your doctor.<br />&bull; a rash, difficulty breathing, fainting or swelling of the face and throat. This is a sign that you may have<br />developed an allergic reaction.<br />&bull; severe skin reactions such as blistering of the skin, mouth, lips, eyes and genitals (symptoms of a rare allergic<br />reaction called Stevens-Johnson syndrome/toxic epidermal necrolysis).<br />&bull; yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender abdomen or loss of appetite.<br />These may be signs that your liver may not be working properly.<br />&bull; Henoch-Schonlein purpura (a rash which appears as purple spots on the skin).<br />&bull; Drug reaction with eosinophilia and systemic symptoms (DRESS). This can include symptoms such as rash,<br />fever abnormal blood count and inflammation of internal organs.<br />Common side effects (may affect up to 1 in 10 people)<br />&bull; headache<br />&bull; difficulty sleeping<br />&bull; changes in sense of taste<br />&bull; stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea<br />&bull; a change in the way the liver works<br />&bull; skin rash<br />&bull; increased sweating<br />Uncommon side effects (may affect up to 1 in 100 people)<br />&bull; swelling, redness or itchiness of the skin. Sometimes brown scales may appear oral or vaginal &#39;thrush&#39; (a<br />fungal infection)<br />&bull; reduction in the level of certain blood cells (which can make infections more likely or increase the risk of<br />bruising or bleeding)<br />&bull; loss of appetite, heartburn, bloating, constipation, wind<br />&bull; anxiety, nervousness, drowsiness, tiredness, dizziness, tremor or shaking<br />&bull; ringing in the ears, problems with hearing<br />&bull; vertigo<br />&bull; inflammation of the mouth or tongue<br />&bull; dry mouth<br />&bull; joint pain<br />&bull; muscle pain or loss of muscle tissue. If you suffer from myasthenia gravis (a condition in which the muscles<br />become weak and tire easily) klare may worsen these symptoms<br />&bull; chest pain or changes in heart rhythm such as palpitations<br />&bull; a change in the levels of products produced by the kidney,<br />&bull; a change in the levels of certain cells or products found in the blood.<br />Not known side effects (frequency cannot be estimated from the available data)<br />&bull; acne<br />&bull; Henoch-Schonlein purpura (a rash which appears as purple spots on the skin)<br />&bull; inflammation of the pancreas<br />&bull; confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or panicking, depression,<br />abnormal dreams or nightmares<br />&bull; convulsion (fits)<br />&bull; paraesthesia, more commonly known as &#39;pins and needles&#39;<br />&bull; loss of taste or smell or inability to smell properly<br />&bull; a change in the levels of products made by the liver, inflammation of the liver or an inability of the liver to<br />function properly (you may notice yellowing of the skin, dark urine, pale stools or itchiness of the skin)<br />&bull; inflammation of the kidney or an inability of the kidney to function properly (you may notice tiredness, swelling<br />or puffiness in the face, abdomen, thighs or ankles or problems with urination).<br />&bull; low blood sugar levels<br />&bull; deafness<br />&bull; discolouration of the tongue and/or teeth<br />Consult your doctor immediately if you develop any of these problems or have any other unexpected or unusual<br />symptoms.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in<br />this leaflet. You can also report side effects directly to The National Pharmacovigilance and Drug Safety Centre<br />(NPC)<br />To report any side effect(s):<br />&bull;Saudi Arabia: - The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 30&deg;C. Keep in a dry place in the original package.<br />Do not use Klare Tablets after the expiry date stated on the carton or label.<br />Medicines should not be disposed of via waste water or household waste. Ask your pharmacist how to dispose<br />of medicines no longer required. These measures will help to protect the environment</p><p>The tablets also contain inactive ingredients microcrystalline cellulose, Croscarmellose Sodium, Povidone K<br />30, Pregelatinizaed Maize Starch, Colloidal Anhydrous Silica, Talc Powder, Stearic Acid, Magnesium Stearate<br />and the coating material Opadry OYS 32924 (Yellow).<br />Klare 500mg tablets are yellow coloured, compact, biconvex, epileptical oval, engraved on one side with code<br />&ldquo;C43&rdquo; and scored both sides.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Klare 500mg tablets are available in blister strips of 14 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer:<br />Middle East Pharmaceutical Company LTD. (Avalon Pharma) Riyadh, KSA.<br />TEL: +966(011)2653948.</p><p><br />Marketing Authorisation Holder (MAH):<br />Middle East Distribution Company LTD. (MEDICO) Riyadh, KSA.<br />TEL: +966(011)2653948.<br />For any information about this medicinal product, please contact the Marketing Authorization Holder.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تنتمي أقراص كلیر إلى مجموعة أدویة تسمى بالمضادات الحیویة ماكروماید، توقف ھذه المضادات الحیویة نمو البكتیریا (البق) التي تسبب<br />الالتھابات .<br />تستخدم أقراص كلیر لعلاج الالتھابات التالیة :<br />&bull; الالتھابات الصدریة مثل التھاب الشعب الھوائیة والالتھاب الرئوي .<br />&bull; التھابات الحلق والجیوب الأنفیة،<br />&bull; الالتھابات الجلدیة والتھابات الأنسجة الرخوة،<br />&bull; التھابات ھیلیكوباكتر بیلوري المصاحبة لقرحة الاثنى عشر .<br />توصف أقراص كلیر للأشخاص البالغین والأطفال في سن ١٢ عامًا فما فوق .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یمنع استعمال أقراص كلیر في الحالات التالیة<br />&bull; الحساسیة ضد الكلاریثرومیسین، أو المضادات الحیویة الماكروماید الأخرى مثل الأریثرومیسین، أو أزیثرومیسین، أو أي<br />مكونات أخرى في أقراص كلیر .<br />&bull; استعمال أدویة مثل الإرغوتامین، أو أقراص ثنائي ھیدروأرغوتامین، أو استعمال أجھزة استنشاق الإرغوتامین في حالات<br />الصداع النصفي .<br />&bull; استعمال أدویة تسمى تیرفینادین، أو استیمیزول (تستعمل على نطاقٍ واسع في حالات الحمى أو الحساسیة)، أو سیسابرید<br />(لأمراض المعدة)، أو بیموزید (لمشكلات الصحة العقلیة) نظرًا لأن الجمع بین ھذه الأدویة یمكن في بعض الأحیان أن یتسبب في الإصابة<br />بإضطرابات خطیرة في ضربات القلب .<br />معروفة باسم الستاتین (عقار مُخفِّص لمستوى &quot;HMG-CoA&quot; &bull; استعمال وفاستاتین أو سیمفاستاتین (مثبتطات مختزلة<br />الكولیسترول)، المستخدمة لعلاج المستویات المنخفضة من الكولیسترول (النوع الخاص بالدھون) في الدم) .<br />&bull; الإصابة بمستویات منخفضة من البوتاسیوم في الدم (تعرف الحالة باسم نقص بوتاسیوم الدم) .<br />&bull; الإصابة بعدم انتظام ضربات القلب<br />&bull; الإصابة بمرض عضال في الكبد مع مرض في الكلى<br />یُمنع استعمال أقراص كلیر في الأطفال دون ١٢ عامًا .<br />لتحذیرات والاحتیاطات :<br />&bull; حالات الحمل والرضاعة الطبیعیة<br />&bull; الإصابة أو التعرض للإصابة بالالتھابات الفطریة (مثل الثلاع )<br />&bull; مشكلات في الكبد أو الكلى<br />إذا كانت أي من ھذه الحالات موجودة، یجب استشارة الطبیب قبل استعمال أقراص كلیر .<br />الأدویة الأخرى وأقراص كلیر :<br />یُمنع استعمال أقراص كلیر إذا كان المریض یتناول أیًا من الأدویة المدرجة في القسم أعلاه &quot;یمنع استعمال أقراص تابلت في الحالات التالیة&quot;؛<br />یجب إخبار الطبیب في حالة استعمال الأدویة التالیة، نظرًا لأن الجرعة الموصوفة قد تكون ھناك حاجة إلى تغییرھا أو إلى إجراء فحوصات<br />دوریة .<br />ھناك حاجة إلى العنایة في حالة استعمال<br />&bull; الدیجوكسین أو دیسوبیرامید أو الكینیدین (المستخدمة لعلاج أمراض القلب)<br />&bull; كاربامازیبین، فالبروات، الفینوباربیتال أو الفینیتوین (لعلاج حالات الصرع)<br />معروفة باسم الستاتین)، تُستخدم لعلاج المستویات &quot;HMG-CoA&quot; &bull; أتورفاستاتین، رسیوفاستاتین (مثبتطات مختزلة<br />المنخفضة من الكولیسترول (النوع الخاص بالدھون) في الدم). یمكن أن تتسبب الستاتینات (العقاقیر المخفضة للكولیسترول) في الإصابة<br />باعتلال الربیدات (وھي حالة تتسبب في انھیار النسیج العضلي الذي قد یؤدي إلى الفشل الكلوي)، ویجب ذِكر علامات الاعتلال العضلي (ألم أو<br />ضعف في العضلات).<br />&bull; الثیوفیلین (المستخدم في المرضى الذین یعانون من صعوبات في التنفس مثل الربو)<br />&bull; تریازولام، الألبرازولام أو میدازولام (المھدئات)<br />&bull; السیلوستازول (مستخدم في علاج ضعف الدورة الدمویة)<br />&bull; میثیل بریدنیزولون (كورتیكوستیروید)<br />&bull; مضادات التخثر الفمویة (مثل الوارفارین المستخدم في ترقیق الدم)<br />&bull; النیتجلنید أو البیوجلیتازون أو الریباجلینید أو روزیجلیتازون أو الأنسولین (المستخدمة في خفض مستویات السكر في الدم)<br />&bull; السیلدینافیل والفاردنفیل والتادالافیل (المستخدمة في علاج العجز الجنسي عند الذكور البالغین، أو لعلاج ارتفاع ضغط الدم<br />الشریاني (ارتفاع ضغط الدم في الأوعیة الدمویة للرئتین)<br />&bull; فینبلاستین (التي تستخدم لعلاج السرطان)<br />&bull; أومیبرازول (لعلاج عسر الھضم وقرحة المعدة) ما لم یصفھ الطبیب لعلاج التھاب ھیلیكوباكتر بیلوري المصاحب لقرحة<br />الإثنى عشر.<br />&bull; السیكلوسبورین أو سیرولیموس أو تاكرولیموس (مثبطات المناعة)<br />&bull; الإترافیرین إیفافیرنز، نیفیرابین، ریتونافیر، زیدوفودین، اتازنفیر، ساكوینافیر (العقاقیر المضادة للفیروسات المستخدمة في<br />علاج فیروس نقص المناعة البشریة)<br />&bull; ریفامبیسین أو ریفابینتین أو فلوكونازول أو الإیتراكونازول أو ریفابیتین (المستخدمة في علاج التھابات بكتیریة معینة)<br />&bull; التولتیروداین (لعلاج النشاط المفرط للمثانة)<br />&bull; فیرابامیل، أملودیبین، دیلتیازیم (ارتفاع ضغط الدم)<br />&bull; نبتة سانت جون (منتج عشبي لعلاج الاكتئاب)<br />&bull; الكولشیسین (یؤخذ عادة لمرض النقرس)<br />&bull; الأمینوغلیكوزیدات (مجموعة من المضادات الحیویة لعلاج أنواع معینة من البكتیریا على سبیل المثال جنتامیسین،<br />النیومایسین)<br />لا یتفاعل عقار كلیر مع وسائل منع الحمل عن طریق الفم<br />برجاء إبلاغ الطبیب أو الصیدلي في حالة استعمال أدویة أخرى على الأقل في الآونة الأخیرة، بما في ذلك تلك الأدویة المستعملة دون روشتة.<br />تناول أقراص كلیر مع الطعام والشراب. یمكن استعمال أقراص كلیر مع أو دون الطعام.<br />الحمل والرضاعة الطبیعیة الخصویة<br />في حالة الاعتقاد بوجود حمل أو التخطیط لإنجاب طفل، یجب طلب مشورة الطبیب أو الصیدلي قبل استعمال ھذا العقار، نظرًا لعدم التأكد من<br />سلامة تناولھ مع حالات الحمل أو الرضاعة الطبیعیة.<br />یجب استشارة الطبیب أو الصیدلي قبل استعمال أي دواء<br />القیادة واستعمال الأدویة<br />قد یحدث دوار أو نعاس عند استعمال أقراص كلیر، لذا، في حالة ظھور ھذه الأعراض، یجب الامتناع عن القیادة أو تشغیل الآلات أو القیام بأي<br />شيء یلزم معھ الانتباه.</p><p>٣. الجرعات:<br />أ- قرص واحد یحتوي على ٥٠٠ ملغم.<br />ب- نصف قرص یحتوي على ٢٥٠ ملغم.<br />ملاحظة: لتقسم القرص إلى نصفان ضع التجویف الموجود بمنتصف القرص على حافة سطح قاسي واضغط بإبھامك یمین ویسارالتجویف وسیتم<br />فصل القرص إلى نصفان متساویان.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استعمال ھذا الدواء.<br />یُمنع الأطفال دون سن ١٢ عامًا من تناول ھذه الأقراص. یقوم الطبیب بوصف دواءٍ آخر مناسب للطفل.<br />تختلف الجرعة وفقًا للحالة، وتحدد بواسطة الصیدلي. یجب تناول ھذه الأقراص بكل دقة على النحو الموصوف بواسطة الطبیب، ویجب<br />الرجوع إلى الطبیب او الصیدلي في حالة عدم معرفة الجرعة بشكلٍ دقیق.<br />یجب ابتلاع أقراص كلیر مع ما لایقل عن نصف كوب من الماء.<br />&bull; لعلاج التھابات الصدر أو الحلق أو الجیوب الأنفیة، والتھابات الجلد والأنسجة الرخوة:<br />الجرعة المعتادة لأقراص كلیر للأشخاص البالغین والأطفال فوق ١٢ عامًا ھي ٢٥٠ ملغم مرتین یومیًا لمدة ٦ إلى ١٤ یومًا، بمعنى ٢٥٠ ملغم<br />(نصف قرص) صباحا و ٢٥٠ ملغم (نصف قرص) مساءا. وقد یوصي الطبیب برفع الجرعة إلى ٥٠٠ ملغم ( قرص واحد) في الصباح و ٥٠٠<br />ملغم (قرص واحد) في المساء في حالة العدوى الشدیدة.<br />&bull; لعلاج التھابات ھیلیكوباكتر بیلوري المصاحبة بقرحة الاثني عشر:<br />ھناك عدد من مجموعات العلاج الفعالة المتاحة لعلاج التھابات ھیلیكوباكتر بیلوري، حیث یتم تناول أقراص كلیر مع عقار واحد أو عقارین<br />آخرین. تشمل ھذه المجموعات ما یلي، وعادة ما یتم تناولھا خلال مدة ٦ إلى ١٤ یومًا:<br />أ) قرص كلیر واحد ٥٠٠ ملغم مرتین یومیًا مع أموكسیسیلین ١٠٠٠ ملغم یتم تناولھ مرتین یومیًا بالإضافة إلى لانسوبرازول ٣٠ ملغم مرتین<br />یومیًا.<br />ب) قرص كلیر واحد ٥٠٠ ملغم مرتین یومیًا مع میترونیدازول ٤٠٠ ملغم مرتین یومیًا بالإضافة إلى لانسوبرازول ٣٠ ملغم مرتین یومیًا.<br />ج) قرص كلیر واحد ٥٠٠ ملغم مرتین یومیًا مع أموكسیسیلین ١٠٠٠ ملغم مرتین یومیًا، أو میترونیدازول ٤٠٠ ملغم مرتین یومیًا بالإضافة إلى<br />أومیبرازول ٤٠ ملجم مرة واحدة یومیًا.<br />د) قرص كلیر واحد ٥٠٠ ملغم مرتین یومیًا مع أموكسیسیلین ١٠٠٠ ملغم مرتین یومیًا، بالإضافة إلى أومیبرازول ٢٠ ملغم مرة واحدة یومیًا.<br />ھ) قرص كلیر واحد ٥٠٠ ملغم ٣ مرات یومیًا مع أومیبرازول ٤٠ ملغم مرة واحدة یومیًا.<br />قد تختلف مجموعة العلاج عن تلك المذكورة أعلاه. سوف یحدد الطبیب المجموعة المناسبة أكثر للحالة. في حالة عدم معرفة الأقراص اللازم<br />تناولھا أو المدة، یجب استشارة الطبیب.</p><p>الجرعة للمرضى المصابین بالفشل الكلوي:<br />الجرعة القصوى الموصاة یجب خفضھا بشكل یتناسب مع حالة الفشل الكلوي. في المرضى المصابین بفشل كلوي بمعدل التخلص من الكریاتینین أقل<br />من ٣٠ مل/دقیقة، یجب خفض الجرعة لھم إلى النصف. أي یتم خفض الجرعة إلى ٢٥٠ ملغم (نصف قرص) یومیًا أو في حالات العدوى الشدیدة<br />إلى ٢٥٠ ملغم (نصف قرص) صباحًا و ٢٥٠ ملغم (نصف قرص) مساءا. یجب وقف العلاج نھائیًا بعد فترة ١٤ یوم لھذه الفئة من المرضى.<br />في حالة تناول أقراص كلیر أكثر من المسموح بھ<br />في حالة ابتلاع عددٍ من الأقراص معًا، أو ابتلاع الطفل لأي من ھذه الأقراص، یجب الاتصال بالطبیب أو الصیدلي أو قسم الطوارئ بالمستشفى على<br />الفور. قد تتسب الجرعة الزائدة من أقراص كلیر على الأرجح في التقیؤ وآلام في المعدة.<br />في حالة نسیان تناول أقراص كلیر:<br />في حالة نسیان تناول الجرعة، یجب أخذھا فور تذكر ذلك، وإذا كان ذلك في وقت تناول الجرعة التالیة، لا یجب تناول الجرعة المنسیة مع الاستمرار<br />في الإجراءات المعتادة، ولا یجب تناول جرعة مضاعفة لتعویض الجرعة المنسیة.<br />في حالة التوقف عن تناول أقراص كلیر: یجب تناول الدواء طالما أمر الطبیب بذلك، وھذا سیستمر عادة لمدة ٦ إلى ١٤ یومًا وفقًا لنوع وشدة<br />الإصابة، ومن المھم عدم التوقف عن تناول الدواء للشعور بالتحسن فقط، نظرًا لأن العدوى قد تعود.<br />في حال وجود أي أسئلة إضافیة حول استخدام ھذا الدواء، برجاء استشارة الطبیب أو الصیدلي أو الممرضة.<br />في حالة وجود أي مشاكل في الكلى، قد تحتلف الجرعة، ولا یجب تغییرھا ما لم یطلب الطبیب ذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما ھو الحال مع جمیع الأدویة، یمكن أن یتسبب ھذا الدواء في ظھور آثار جانبیة، على الرغم من عدم ظھورھا في جمیع الأشخاص .<br />إذا ظھرت أي من الآثار التالیة، یجب التوقف فورًا عن تناول أقراص كلیر وإبلاغ الطبیب، أو الذھاب إلى قسم الطوارئ في أقرب مستشفى :<br />&bull; الإسھال الشدید أو لفتراتٍ طویلة وقد یكون مصحوبًا بدم أو مخاط. قد یحدث الإسھال بعد أكثر من شھرین من العلاج<br />بالكلاریثرومیسین، وفي ھذه الحالة یجب البقاء على اتصال مع الطبیب .<br />&bull; طفح جلدي، وصعوبة في التنفس، والإغماء أو تورم في الوجھ والحلق. قد تكون ھذه علامة على الإصابة برد الفعل<br />التحسسي .<br />&bull; ردود فعل تحسسیة حادة في الجلد مثل تقرحات في الجلد والفم والشفتین والعینین والأعضاء التناسلیة (أعراض الحساسیة<br />النادرة المسماة بمتلازمة ستیفنز جونسون / انحلال البشرة السمي) .<br />&bull; اصفرار الجلد (الیرقان)، أو تھیج الجلد، أو البراز الشاحب، أو البول الداكن، أو ضعف الجدار البطني أو فقدان الشھیة. قد<br />تكون ھذه علامات على عدم عمل الكبد بكفاءة.<br />&bull; ھینوخ شونلاین (الطفح الجلدي الذي یظھر على شكل بقع أرجوانیة على الجلد) .<br />&bull; متلازمة دریس، وقد تشمل أعراض مثل الطفح الجلدي، وحمى عدد كرات الدم غیر الطبیعیة، والتھاب الأعضاء الداخلیة.<br />الآثار الجانبیة الشائعة (قد تظھر في شخص واحد من بین ١٠ أشخاص)<br />&bull; صداع<br />&bull; النوم بصعوبة<br />&bull; تغیُّرات في حاسة التذوق<br />&bull; مشاكل في المعدة مثل الشعور بالإعیاء والتقیؤ، وألم في المعدة وعسر الھضم<br />&bull; تغیُّر في طریقة عمل الكبد<br />&bull; طفح جلدي<br />&bull; زیادة التعرق<br />الآثار الجانبیة غیر الشائعة (قد تظھر في شخص واحد من بین ١٠٠ شخص)<br />&bull; تورم أو احمرار أو حكة في الجلد. قد تظھر في بعض الأحیان قشور بنیة على الفم أو المھبل (القلاع) (التھابات فطریة)<br />&bull; انخفاض مستوى بعض خلایا الدم (ما یمكن أن یتسبب في الإصابة بالالتھابات أو زیادة خطر الإصابة بالكدمات أو<br />النزیف)<br />&bull; فقدان الشھیة وحرقة المعدة والانتفاخ والإمساك والریح<br />&bull; القلق أو العصبیة أو الخمول أو التعب أو الدوخة أو الرعشة أو الاھتزاز<br />&bull; طنین في الأذن ومشاكل في السمع<br />&bull; الدوار<br />&bull; التھاب في الفم أو اللسان<br />&bull; جفاف الفم<br />&bull; آلام في المفاصل<br />&bull; ألم في العضلات أو فقدان الأنسجة العضلیة. إذا كانت ھناك إصابة بالوھن العضلي الحاد (ھو حالة تصبح فیھا العضلات<br />ضعیفة وتتمزق بسھولة)، قد یؤدي استعمال كلیر لتفاقم ھذه الأعراض.<br />&bull; ألم في الصدر أو تغیُّرات في ضربات القلب مثل الخفقان<br />&bull; تغیُّر في مستویات نواتج الكلى<br />&bull; تغیُّر في مستویات بعض الخلایا أو النواتج في الدم<br />الآثار الجانبیة غیر المعروفة (لا یمكن تقدیر تكرار ظھورھا من البیانات المتاحة)<br />&bull; حب الشباب<br />&bull; ھینوخ شونلاین (الطفح الجلدي الذي یظھر على شكل بقع أرجوانیة على الجلد)<br />&bull; التھاب البنكریاس<br />&bull; الارتباك، واختلال التوجیھ، والھلوسة (رؤیة الأشیاء)، وتغیُّر في الإحساس بالواقع أو ھلع، والاكتئاب، والأحلام غیر<br />الطبیعیة أو الكوابیس<br />&bull; تشنج (نوبات)<br />&bull; المذل أو ما یعرف أكثر بنظیر الصرع<br />&bull; فقدان التذوق أو الشم أو عدم القدرة على الشم جیدًا<br />&bull; تغیُّر في مستویات نواتج الكبد، أو التھاب في الكبد، أو عدم قدرة الكبد على أداء وظائفھ بشكلٍ صحیح (قد یُلاحظ وجود<br />اصفرار في الجلد أو بول داكن أو براز شاحب أو حكة في الجلد)<br />&bull; التھاب في الكلى، أو عدم قدرة الكلى على أداء وظائفھا بشكلٍ صحیح (قد یُلاحظ الشعور بالتعب أو تورم أو انتفاخ في الوجھ<br />أو البطن أو الفخذین أو الكاحلین أو مشاكل في التبول).<br />&bull; انخفاض في مستویات السكر في الدم<br />&bull; الصمم<br />&bull; تغیُّر لون اللسان و/أو الأسنان<br />یجب استشارة الطبیب على الفور إذا ظھرت أي من ھذه المشاكل، أو ظھور أي أعراض غیر متوقعة أو غیر طبیعیة.</p><p>الإبلاغ عن الآثار الجانبیة<br />إذا ظھرت أي من الآثار الجانبیة، یجب التحدث مع الطبیب أو الصیدلي، ویشمل ھذا أي آثار جانبیة ممكنة غیر مذكورة في ھذه النشرة.<br />كما یمكن إبلاغ المركز الوطني للتیقظ والسلامة الدوائیة مباشرة عن الآثار الجانبیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تحفظ بعیدًا عن متناول الأطفال<br />یُخزَّن في درجة حرارة أقل من ٣٠ &deg; مئویة، ویحفظ في مكان جاف في العبوة الأصلیة.<br />یُحظر استعمال أقراص كلیر بعد تاریخ انتھاء الصلاحیة على العبوة أو الملصق<br />لا یجب التخلص من الأدویة في میاه الصرف الصحي أو قمامة المنزل. یجب الاستفسار من الصیدلي عن طریقة التخلص من الأدویة التي لم تعد مطلوبة. ھذه<br />الإجراءات تساعد على الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتویات أقراص كلیر<br />- المادة الفعالة ھي كلاریثرومیسین ٥٠٠ ملغم.<br />- المكونات الأخرى للقرص ھي میكروكریستالین سیلولوز، كروسكارمیلوس الصودیوم،والبوفیدون ك ٣٠ ، والنشا المعدل (مسبق التجلتن)،<br />أصفر) ) OYS- والسیلیكا الغرویة اللامائیة، وبودرة التلك، وحامض دھني، وستیرات الماغنسیوم، وأوبادراي 32924</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص كلیر ٥٠٠ ملغم صفراء اللون ومدمجة ومحدبة الوجھین وبیضاویة الشكل، ومنقوش على أحد جوانبھا الكود *C43* مع نقوش على الجانبین.</p><p>أقراص كلیر ٥٠٠ ملغم متوفرة في شرائط یحتوي كلٌ منھا على ١٤ قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة الشرق الأوسط للتوزیع المحدودة&nbsp;(MEDICO)<br />الریاض، المملكة العربیة السعودیة<br />+٩٦٦ (٠١١) تلیفون: ٤٦٥٣١٤٤<br />الشركات المصنعة<br />شركة الشرق الأوسط للصناعات الدوائیة المحدودة (أفالون فارما)<br />الریاض، المملكة العربیة السعودیة<br />+٩٦٦ (٠١١) تلیفون: ٢٦٥٣٩٤٨<br />للحصول على مزید من المعلومات عن ھذا المنتج الطبي، یرجى الاتصال بحامل ترخیص التسویق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Klare 500 mg Film-Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active:Clarithromycin.500 mg
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-Coated Tablets.
Yellow, compact, biconvex, epileptical oval tablet, engraved on one side with
code”C43” and scored both sides
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications:<br />Consideration should be given to official guidance on the appropriate use of<br />antibacterial agents.<br />Clarithromycin tablets are indicated in adults and children 12 years and older. (Adult<br />only formulations, e.g. tablets, IV)<br />Clarithromycin Tablets are indicated for treatment of the following infections caused<br />by susceptible organisms Indication include:<br />Lower respiratory tract infections for example: acute and chronic bronchitis, and<br />pneumonia.<br />Upper respiratory tract infections for example: sinusitis and pharyngitis.<br />Clarithromycin is appropriate for initial therapy in community acquired respiratory<br />infections and has been shown to be active in vitro against common and atypical<br />respiratory pathogens as listed in the microbiology section.<br />Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate<br />severity.<br />Clarithromycin in the presence of acid suppression effected by omeprazole or<br />lansoprazole is also indicated for the eradication of H. pylori in patients with<br />duodenal ulcers. See Dosage and Administration section.</p><p>Clarithromycin is usually active against the following organisms in vitro:<br />Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible);<br />Streptococcus pyogenes (Group A beta-hemolytic streptococci); alpha-hemolytic<br />streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae;<br />Streptococcus agalactiae; Listeria monocytogenes.<br />Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae;<br />Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella<br />pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.<br />Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.<br />Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium<br />leprae<br />Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens;<br />Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.<br />Clarithromycin has bactericidal activity against several bacterial strains. The<br />organisms include Haemophilus influenzae; Streptococcus pneumoniae;<br />Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella)<br />catarrhalis; Neisseria gonorrhoeae; H. pylori and Campylobacter spp.<br />The activity of clarithromycin against H. pylori is greater at neutral pH than at acid<br />pH.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dosing:<br />A. One tablet contain 500 mg.<br />B. Half a tablet contain 250 mg.<br />Note: to split tablet place it on a hard surface and press down with one thumb on the<br />left of the dividing groove and the other thumb on the right. The tablet can thus be<br />readily split into halves.<br />Patients with respiratory tract/skin and soft tissue infections<br />Adults: The usual dose is 250 mg twice daily although this may be increased to<br />500mg twice daily in severe infections. The usual duration of treatment is 6 to 14<br />days. (Adult only formulation)<br />Children older than 12 years: As for adults.<br />Children younger than 12 years: Use of clarithromycin tablets are not recommended<br />for children younger than 12 years. Clinical trials have been conducted using&nbsp;clarithromycin paediatric suspension in children 6 months to 12 years of age.<br />Therefore, children under 12 years of age should use clarithromycin paediatric<br />suspension (granules for oral suspension).</p><p>Eradication of H. pylori in patients with duodenal ulcers (Adults)<br />The usual duration of treatment is 6 to 14 days.<br />Triple Therapy:<br />Clarithromycin 500mg twice daily and lansoprazole 30mg twice daily should be given<br />with amoxycillin 1000mg twice daily.<br />Triple Therapy:<br />Clarithromycin 500mg twice daily and lansoprazole 30mg twice daily should be given<br />with metronidazole 400mg twice daily.<br />Triple Therapy:<br />Clarithromycin 500mg twice daily and omeprazole 40mg daily should be given with<br />amoxycillin 1000mg twice daily or metronidazole 400mg twice daily.<br />Triple Therapy:<br />Clarithromycin 500mg twice daily should be given with amoxycillin 1000mg twice<br />daily and omeprazole 20mg daily.<br />Dual Therapy:<br />The usual dose of clarithromycin is 500 mg three times daily for 14 days.<br />Clarithromycin should be administered with oral omeprazole 40 mg once daily. The<br />pivotal study was conducted with omeprazole 40 mg once daily for 28 days.<br />Supportive studies have been conducted with omeprazole 40 mg once daily.<br />Elderly<br />As for adults.<br />Renal impairment<br />Dosage adjustments are not usually required except in patients with severe renal<br />impairment (creatinine clearance &lt; 30 ml/min). If adjustment is necessary, the total<br />daily dosage should be reduced by half, e.g. 250 mg once daily or 250 mg twice daily<br />in more severe infections. Treatment should not be continued beyond 14 days in<br />these patients.<br />Clarithromycin may be given without regard to meals as food does not affect the<br />extent of bioavailability.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clarithromycin is contraindicated in patients with known hypersensitivity to
clarithromycin, to any other macrolide antibiotic drug, or to any of the other  ingredients in the tablets.
Concomitant administration of clarithromycin and ergotamine or dihydroergotamine
is contraindicated, as this may result in ergot toxicity.
Concomitant administration of clarithromycin and any of the following drugs is
contraindicated
: astemizole, cisapride, pimozide and terfenadine as this may result in QT
prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular
fibrillation, and torsades de pointe (see section 4.5).
Clarithromycin should not be given to patients with history of QT prolongation or
ventricular cardiac arrhythmia, including torsades de pointe (see sections 4.4 and
4.5).
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors
(statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due
to increased risk of myopathy, including rhabdomyolysis. Treatment with these
agents should be discontinued during clarithromycin treatment (see section 4.4).
Colchicine is contraindicated in patients with renal or hepatic impairment who are
taking P-glycoprotein or a strong CYP3A4 inhibitor.
Clarithromycin should not be given to patients with hypokalaemia (risk of
prolongation of QT-time).
Clarithromycin should not be used in patients who suffer from severe hepatic failure
in combination with renal impairment.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without<br />carefully weighing the benefits against risk, particularly during the first three months<br />of pregnancy (see section 4.6).<br />Caution is advised in patients with severe renal insufficiency (see section 4.2).<br />Clarithromycin is principally excreted by the liver. Therefore, caution should be<br />exercised in administering this antibiotic to patients with impaired hepatic function.<br />Caution should also be exercised when administering clarithromycin to patients with<br />moderate to severe renal impairment.<br />Cases of fatal hepatic failure (see section 4.8) have been reported. Some patients<br />may have had pre-existing hepatic disease or may have been taking other&nbsp;hepatotoxic medicinal products. Patients should be advised to stop treatment and<br />contact their doctor if signs and symptoms of hepatic disease develop, such as<br />anorexia, jaundice, dark urine, pruritus, or tender abdomen.<br />Pseudomembranous colitis has been reported with nearly all antibacterial agents,<br />including macrolides, and may range in severity from mild to life-threatening.<br />Clostridium difficile- associated diarrhoea (CDAD) has been reported with use of<br />nearly all antibacterial agents including clarithromycin, and may range in severity<br />from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the<br />normal flora of the colon, which may lead to overgrowth of C. difficile. CDAD must be<br />considered in all patients who present with diarrhoea following antibiotic use. Careful<br />medical history is necessary since CDAD has been reported to occur over two<br />months after the administration of antibacterial agents. Therefore, discontinuation of<br />clarithromycin therapy should be considered regardless of the indication. Microbial<br />testing should be performed and adequate treatment initiated. Drugs inhibiting<br />peristalsis should be avoided.<br />Exacerbation of symptoms of myasthenia gravis has been reported in patients<br />receiving clarithromycin therapy.<br />There have been post-marketing reports of colchicine toxicity with concomitant use of<br />clarithromycin and colchicine, especially in the elderly, some of which occurred in<br />patients with renal insufficiency. Deaths have been reported in some such patients<br />(see section 4.5). If concomitant administration of colchicine and clarithromycin is<br />necessary, patients should be monitored for clinical symptoms of colchicine toxicity<br />(see section 4.3).<br />Caution is advised regarding concomitant administration of clarithromycin and<br />triazolobenzodiazepines, such as triazolam, and midazolam (see section 4.5).<br />Caution is advised regarding concomitant administration of clarithromycin with other<br />ototoxic drugs, especially with aminoglycosides. Monitoring of vestibular and auditory<br />function should be carried out during and after treatment.</p><p>Due to the risk for QT prolongation, clarithromycin should be used with caution in<br />patients with coronary artery disease, severe cardiac insufficiency,<br />hypomagnesaemia, bradycardia (&lt;50 bpm), or when co-administered with other<br />medicinal products associated with QT prolongation (see section 4.5). Clarithromycin<br />must not be used in patients with congenital or documented acquired QT<br />prolongation or history of ventricular arrhythmia (see section 4.3).<br />Pneumonia: In view of the emerging resistance of Streptococcus pneumoniae to<br />macrolides, it is important that sensitivity testing be performed when prescribing<br />clarithromycin for community-acquired pneumonia. In hospital-acquired pneumonia,<br />clarithromycin should be used in combination with additional appropriate antibiotics.</p><p>Skin and soft tissue infections of mild to moderate severity: These infections are most<br />often caused by Staphylococcus aureus and Streptococcus pyogenes, both of which<br />may be resistant to macrolides. Therefore, it is important that sensitivity testing be<br />performed. In cases where beta&ndash;lactam antibiotics cannot be used (e.g. allergy),<br />other antibiotics, such as clindamycin, may be the drug of first choice. Currently,<br />macrolides are only considered to play a role in some skin and soft tissue infections,<br />such as those caused by Corynebacterium minutissimum (erythrasma), acne<br />vulgaris, and erysipelas and in situations where penicillin treatment cannot be used.<br />In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-<br />Johnson Syndrome, and toxic epidermal necrolysis, DRESS and Henoch-Schonlein<br />purpura, clarithromycin therapy should be discontinued immediately and appropriate<br />treatment should be urgently initiated.<br />Clarithromycin should be used with caution when administered concurrently with<br />medications that induce the cytochrome CYP3A4 enzyme (see section 4.5).<br />HMG-CoA reductase inhibitors: Concomitant use of clarithromycin with lovastatin or<br />simvastatin is contraindicated (see section 4.3) as these statins are extensively<br />metabolized by CYP3A4 and concomitant treatment with clarithromycin increases<br />their plasma concentration, which increases the risk of myopathy, including<br />rhabdomyolysis. Rare reports of rhabdomyolysis have been reported in patients<br />taking these drugs concomitantly with these statins.<br />If treatment with clarithromycin cannot be avoided, therapy with lovastatin or<br />simvastatin must be suspended during the course of treatment.<br />Caution should be exercised when prescribing clarithromycin with statins.</p><p>In situations where the concomitant use of clarithromycin with statins cannot be<br />avoided, it is recommended to prescribe the lowest registered dose of the statin. Use<br />of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin or<br />pravastatin) should be considered.<br />Oral hypoglycaemic agents/Insulin: The concomitant use of clarithromycin and oral<br />hypoglycaemic agents and/or insulin can result in significant hypoglycaemia. With<br />certain hypoglycaemic drugs such as nateglinide, pioglitazone, repaglinide and<br />rosiglitazone, inhibition of CYP3A enzyme by clarithromycin may be involved and<br />could cause hypolgycemia when used concomitantly. Careful monitoring of glucose is<br />recommended.<br />Oral anticoagulants: There is a risk of serious haemorrhage and significant elevations<br />in International Normalized Ratio (INR) and prothrombin time when clarithromycin is<br />co-administered with warfarin (see section 4.5). INR and prothrombin times should be&nbsp;frequently monitored while patients are receiving clarithromycin and oral<br />anticoagulants concurrently.<br />Use of any antimicrobial therapy, such as clarithromycin, to treat H. pylori infection<br />may select for drug-resistant organisms.<br />Long-term use may, as with other antibiotics, result in colonisation with increased<br />numbers of non-susceptible bacteria and fungi. If superinfections occur, appropriate<br />therapy should be instituted.<br />Attention should also be paid to the possibility of cross resistance between<br />clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of the following drugs is strictly contraindicated due to the potential for<br />severe drug interaction effects:<br />Cisapride, pimozide, astemizole and terfenadine<br />Elevated cisapride levels have been reported in patients receiving clarithromycin and<br />cisapride concomitantly. This may result in QT prolongation and cardiac arrhythmias<br />including ventricular tachycardia, ventricular fibrillation and torsades de pointes.<br />Similar effects have been observed in patients taking clarithromycin and pimozide<br />concomitantly (see section 4.3).<br />Macrolides have been reported to alter the metabolism of terfenadine resulting in<br />increased levels of terfenadine which has occasionally been associated with cardiac<br />arrhythmias, such as QT prolongation, ventricular tachycardia, ventricular fibrillation<br />and torsades de pointes (see section 4.3). In one study in 14 healthy volunteers, the<br />concomitant administration of clarithromycin and terfenadine resulted in 2- to 3-fold<br />increase in the serum level of the acid metabolite of terfenadine and in prolongation<br />of the QT interval which did not lead to any clinically detectable effect. Similar effects<br />have been observed with concomitant administration of astemizole and other<br />macrolides.<br />Ergotamine/dihydroergotamine<br />Post-marketing reports indicate that co-administration of clarithromycin with<br />ergotamine or dihydroergotamine has been associated with acute ergot toxicity<br />characterized by vasospasm, and ischaemia of the extremities and other tissues<br />including the central nervous system. Concomitant administration of clarithromycin<br />and these medicinal products is contraindicated (see section 4.3).<br />Effects of Other Medicinal Products on Clarithromycin<br />Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine,<br />phenobarbital, St John&#39;s wort) may induce the metabolism of clarithromycin. This may<br />result in sub-therapeutic levels of clarithromycin leading to reduced efficacy.<br />Furthermore, it might be necessary to monitor the plasma levels of the CYP3A</p><p>inducer, which could be increased owing to the inhibition of CYP3A by clarithromycin<br />(see also the relevant product information for the CYP3A4 inhibitor administered).<br />Concomitant administration of rifabutin and clarithromycin resulted in an increase in<br />rifabutin, and decrease in clarithromycin serum levels together with an increased risk<br />of uveitis.<br />The following drugs are known or suspected to affect circulating concentrations of<br />clarithromycin; clarithromycin dosage adjustment or consideration of alternative<br />treatments may be required.<br />Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine<br />Strong inducers of the cytochrome P450 metabolism system such as efavirenz,<br />nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the metabolism of<br />clarithromycin and thus lower the plasma levels of clarithromycin, while increasing<br />those of 14-OH-clarithromycin, a metabolite that is also microbiologically active.<br />Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are<br />different for different bacteria, the intended therapeutic effect could be impaired<br />during concomitant administration of clarithromycin and enzyme inducers.<br />Etravirine<br />Clarithromycin exposure was decreased by etravirine; however, concentrations of the<br />active metabolite, 14-OHclarithromycin, were increased. Because 14-OHclarithromycin<br />has reduced activity against Mycobacterium avium complex (MAC),<br />overall activity against this pathogen may be altered; therefore alternatives to<br />clarithromycin should be considered for the treatment of MAC.<br />Fluconazole<br />Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg<br />twice daily to 21 healthy volunteers led to increases in the mean steady-state<br />minimum clarithromycin concentration (Cmin) and area under the curve (AUC) of<br />33% and 18% respectively. Steady state concentrations of the active metabolite 14-<br />OH-clarithromycin were not significantly affected by concomitant administration of<br />fluconazole. No clarithromycin dose adjustment is necessary.</p><p>Ritonavir<br />A pharmacokinetic study demonstrated that the concomitant administration of<br />ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours resulted<br />in a marked inhibition of the metabolism of clarithromycin. The clarithromycin Cmax<br />increased by 31%, Cmin increased 182% and AUC increased by 77% with<br />concomitant administration of ritonavir. An essentially complete inhibition of the<br />formation of 14-OH-clarithromycin was noted. Because of the large therapeutic<br />window for clarithromycin, no dosage reduction should be necessary in patients with<br />normal renal function. However, for patients with renal impairment, the following<br />dosage adjustments should be considered: For patients with CLCR 30 to 60 mL/min<br />the dose of clarithromycin should be reduced by 50%. For patients with CLCR &lt;30</p><p>mL/min the dose of clarithromycin should be decreased by 75%. Doses of<br />clarithromycin greater than 1 gm/day should not be co-administered with ritonavir.<br />Similar dose adjustments should be considered in patients with reduced renal<br />function when ritonavir is used as a pharmacokinetic enhancer with other HIV<br />protease inhibitors including atazanavir and saquinavir (see section below, Bidirectional<br />drug interactions)<br />Effect of Clarithromycin on Other Medicinal Products<br />CYP3A-based interactions<br />Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily<br />metabolised by CYP3A may be associated with elevations in drug concentrations that<br />could increase or prolong both therapeutic and adverse effects of the concomitant<br />drug. Clarithromycin should be used with caution in patients receiving treatment with<br />other drugs known to be CYP3A enzyme substrates, especially if the CYP3A<br />substrate has a narrow safety margin (e.g. carbamazepine) and/or the substrate is<br />extensively metabolised by this enzyme.<br />Dosage adjustments may be considered, and when possible, serum concentrations<br />of drugs primarily metabolised by CYP3A should be monitored closely in patients<br />concurrently receiving clarithromycin.<br />The following drugs or drug classes are known or suspected to be metabolised by the<br />same CYP3A isozyme: alprazolam, astemizole, carbamazepine, cilostazol, cisapride,<br />ciclosporin, disopyramide, ergot alkaloids, lovastatin, methylprednisolone,<br />midazolam, omeprazole, oral anticoagulants (e.g. warfarin), pimozide, quinidine,<br />rifabutin, sildenafil, simvastatin, sirolimus, tacrolimus, terfenadine, triazolam and<br />vinblastine. Drugs interacting by similar mechanisms through other isozymes within<br />the cytochrome P450 system include phenytoin, theophylline and valproate.</p><p>Antiarrhythmics<br />There have been post-marketed reports of torsade de points occurring with the<br />concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms<br />should be monitored for QTc prolongation during co-administration of clarithromycin<br />with these drugs. Serum levels of quinidine and disopyramide should be monitored<br />during clarithromycin therapy.<br />Omeprazole<br />Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole (40<br />mg daily) to healthy adult subjects. The steady-state plasma concentrations of<br />omeprazole were increased (Cmax, AUC0-24, and t1/2 increased by 30%, 89%, and<br />34%, respectively), by the concomitant administration of clarithromycin. The mean<br />24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7<br />when omeprazole was co-administered with clarithromycin.</p><p>Sildenafil, tadalafil and vardenafil</p><p>Each of these phosphodiesterase inhibitors is metabolised, at least in part, by<br />CYP3A, and CYP3A may be inhibited by concomitantly administered clarithromycin.<br />Co-administration of clarithromycin with sildenafil, tadalafil or vardenafil would likely<br />result in increased phosphodiesterase inhibitor exposure. Reduction of sildenafil,<br />tadalafil and vardenafil dosages should be considered when these drugs are coadministered<br />with clarithromycin.<br />Theophylline, carbamazepine<br />Results of clinical studies indicate that there was a modest but statistically significant<br />(p&le; 0.05) increase of circulating theophylline or carbamazepine levels when either of<br />these drugs were administered concomitantly with clarithromycin. Dose reduction<br />may need to be considered.<br />Tolterodine<br />The primary route of metabolism for tolterodine is via the 2D6 isoform of cytochrome<br />P450 (CYP2D6). However, in a subset of the population devoid of CYP2D6, the<br />identified pathway of metabolism is via CYP3A. In this population subset, inhibition of<br />CYP3A results in significantly higher serum concentrations of tolterodine. A reduction<br />in tolterodine dosage may be necessary in the presence of CYP3A inhibitors, such as<br />clarithromycin in the CYP2D6 poor metaboliser population.</p><p>Triazolobenzodiazepines (e.g., alprazolam, midazolam, triazolam)<br />When midazolam was co-administered with clarithromycin tablets (500 mg twice<br />daily), midazolam AUC was increased 2.7-fold after intravenous administration of<br />midazolam and 7-fold after oral administration. Concomitant administration of oral<br />midazolam and clarithromycin should be avoided. If intravenous midazolam is coadministered<br />with clarithromycin, the patient must be closely monitored to allow dose<br />adjustment. The same precautions should also apply to other benzodiazepines that<br />are metabolised by CYP3A, including triazolam and alprazolam. For benzodiazepines<br />which are not dependent on CYP3A for their elimination (temazepam, nitrazepam,<br />lorazepam), a clinically important interaction with clarithromycin is unlikely.<br />There have been post-marketing reports of drug interactions and central nervous<br />system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of<br />clarithromycin and triazolam. Monitoring the patient for increased CNS<br />pharmacological effects is suggested.<br />Other drug interactions<br />Colchicine<br />Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein<br />(Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp.<br />When clarithromycin and colchicine are administered together, inhibition of Pgp<br />and/or CYP3A by clarithromycin may lead to increased exposure to colchicine.</p><p>Patients should be monitored for clinical symptoms of colchicine toxicity (see section<br />4.4).<br />Digoxin<br />Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp).<br />Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are<br />administered together, inhibition of Pgp by clarithromycin may lead to increased<br />exposure to digoxin. Elevated digoxin serum concentrations in patients receiving<br />clarithromycin and digoxin concomitantly have also been reported in post marketing<br />surveillance. Some patients have shown clinical signs consistent with digoxin toxicity,<br />including potentially fatal arrhythmias. Serum digoxin concentrations should be<br />carefully monitored while patients are receiving digoxin and clarithromycin<br />simultaneously.<br />Zidovudine<br />Simultaneous oral administration of clarithromycin tablets and zidovudine to HIVinfected<br />adult patients may result in decreased steady-state zidovudine<br />concentrations. Because clarithromycin appears to interfere with the absorption of<br />simultaneously administered oral zidovudine, this interaction can be largely avoided<br />by staggering the doses of clarithromycin and zidovudineto allow for a 4-hour interval<br />between each medication. This interaction does not appear to occur in paediatric<br />HIV-infected patients taking clarithromycin suspension with zidovudine or<br />dideoxyinosine. This interaction is unlikely when clarithromycin is administered via<br />intravenous infusion.<br />Phenytoin and Valproate<br />There have been spontaneous or published reports of interactions of CYP3A<br />inhibitors, including clarithromycin with drugs not thought to be metabolised by<br />CYP3A (e.g. phenytoin and valproate). Serum level determinations are<br />recommended for these drugs when administered concomitantly with clarithromycin.<br />Increased serum levels have been reported.</p><p>Bi-directional drug interactions<br />Atazanavir<br />Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there<br />is evidence of a bi-directional drug interaction. Co-administration of clarithromycin<br />(500 mg twice daily) with atazanavir (400 mg once daily) resulted in a 2-fold increase<br />in exposure to clarithromycin and a 70% decrease in exposure to 14-OHclarithromycin,<br />with a 28% increase in the AUC of atazanavir. Because of the large<br />therapeutic window for clarithromycin, no dosage reduction should be necessary in<br />patients with normal renal function. For patients with moderate renal function<br />(creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should be<br />decreased by 50%. For patients with creatinine clearance &lt;30 mL/min, the dose of<br />clarithromycin should be decreased by 75% using an appropriate clarithromycin<br />formulation. Doses of clarithromycin greater than 1000 mg per day should not be coadministered with protease inhibitors.</p><p>Itraconazole<br />Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading<br />to a bidirectional drug interaction. Clarithromycin may increase the plasma levels of<br />itraconazole, while itraconazole may increase the plasma levels of clarithromycin.<br />Patients taking itraconazole and clarithromycin concomitantly should be monitored<br />closely for signs or symptoms of increased or prolonged pharmacologic effect.<br />Saquinavir<br />Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and there<br />is evidence of a bi-directional drug interaction. Concomitant administration of<br />clarithromycin (500 mg twice daily) and saquinavir (soft gelatin capsules, 1200 mg<br />three times daily) to 12 healthy volunteers resulted in steady-state AUC and Cmax<br />values of saquinavir which were 177% and 187% higher than those seen with<br />saquinavir alone. Clarithromycin AUC and Cmax values were approximately 40%<br />higher than those seen with clarithromycin alone. No dose adjustment is required<br />when the two drugs are co-administered for a limited time at the doses/formulations<br />studied. Observations from drug interaction studies using the soft gelatin capsule<br />formulation may not be representative of the effects seen using the saquinavir hard<br />gelatin capsule. Observations from drug interaction studies performed with saquinavir<br />alone may not be representative of the effects seen with saquinavir/ritonavir therapy.<br />When saquinavir is co-administered with ritonavir, consideration should be given to<br />the potential effects of ritonavir on clarithromycin (see section 4.5: Ritonavir).<br />Verapamil<br />Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients<br />taking clarithromycin and verapamil concomitantly.<br />Clarithromycin has been shown not to interact with oral contraceptives.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>pregnancy category: C<br />The safety of clarithromycin during pregnancy and breast feeding of infants has not<br />been established. Based on variable results obtained from studies in mice, rats,<br />rabbits and monkeys, the possibility of adverse effects on embryofoetal<br />development cannot be excluded. Therefore, use during pregnancy is not advised<br />without carefully weighing the benefits against risk. Clarithromycin is excreted into<br />human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use<br />machines. The potential for dizziness, vertigo, confusion and disorientation, which<br />may occur with the medication, should be taken into account before patients drive or<br />use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile<br />The most frequent and common adverse reactions related to clarithromycin therapy<br />for both adult and peadiatric populations are abdominal pain, diarrhoea, nausea,<br />vomiting and taste perversion. These adverse reactions are usually mild in intensity<br />and are consistent with the known safety profile of macrolide antibiotics (see section<br />b of section 4.8).<br />There was no significant difference in the incidence of these gastrointestinal adverse<br />reactions during clinical trials between the patient population with or without preexisting<br />mycobacterial infections.<br />b. Tabulated summary of adverse reactions<br />The following table displays adverse reactions reported in clinical trials and from postmarketing<br />experience with clarithromycin immediate-release tablets, granules for oral<br />suspension, powder for solution for injection, extended-release tablets and modifiedrelease<br />tablets.<br />The reactions considered at least possibly related to clarithromycin are displayed by<br />system organ class and frequency using the following convention: very common<br />(&ge;1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge;1/1,000 to &lt; 1/100) and not<br />known (adverse reactions from post-marketing experience; cannot be estimated from<br />the available data). Within each frequency grouping, adverse reactions are presented<br />in order of decreasing seriousness when the seriousness could be assessed.</p><p>1 ADRs reported only for the Powder for Solution for Injection formulation<br />2ADRs reported only for the Extended-Release Tablets formulation<br />3 ADRs reported only for the Granules for Oral Suspension formulation<br />4 ADRs reported only for the Immediate-Release Tablets formulation<br />5,8,10,11,12See section a)<br />6,7,9See section c)</p><p>* Because these reactions are reported voluntarily from a population of uncertain<br />size, it is not always possible to reliably estimate their frequency or establish a causal<br />relationship to drug exposure. Patient exposure is estimated to be greater than 1<br />billion patient treatment days for clarithromycin.<br />**In some of the reports of rhabdomyolysis, clarithromycin was administered<br />concomitantly with other drugs known to be associated with rhabdomyolysis (such as<br />statins, fibrates, colchicine or allopurinol).<br />c. Description of selected adverse reactions<br />Injection site phlebitis, injection site pain, vessel puncture site pain, and injection site<br />inflammation are specific to the clarithromycin intravenous formulation.<br />In very rare instances, hepatic failure with fatal outcome has been reported and<br />generally has been associated with serious underlying diseases and/or concomitant<br />medications (see section 4.4).<br />A special attention to diarrhoea should be paid as Clostridium difficile-associated<br />diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents<br />including clarithromycin, and may range in severity from mild diarrhoea to fatal colitis.<br />(see section 4.4)</p><p>In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-<br />Johnson Syndrome and toxic epidermal necrolysis, clarithromycin therapy should be<br />discontinued immediately and appropriate treatment should be urgently initiated (see<br />section 4.4).<br />As with other macrolides, QT prolongation, ventricular tachycardia, and torsade de<br />pointes have rarely been reported with clarithromycin (see section 4.4 and 4.5).<br />Pseudomembranous colitis has been reported with nearly all antibacterial agents,<br />including clarithromycin, and may range in severity from mild to life threatening.<br />Therefore, it is important to consider this diagnosis in patients who present with<br />diarrhoea subsequent to the administration of antibacterial agents (see section 4.4).<br />In some of the reports of rhabdomyolysis, clarithromycin was administered<br />concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3 and 4.4).<br />There have been post-marketing reports of colchicine toxicity with concomitant use of<br />clarithromycin and colchicine, especially in elderly and/or patients with renal<br />insufficiency, some with a fatal outcome. (see sections 4.4 and 4.5).</p><p>There have been rare reports of hypoglycaemia, some of which have occurred in<br />patients on concomitant oral hypoglycaemic agents or insulin (see section 4.4 and<br />4.5).<br />There have been post-marketing reports of drug interactions and central nervous<br />system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of<br />clarithromycin and triazolam. Monitoring the patient for increased CNS<br />pharmacological effects is suggested (see section 4.5).<br />There is a risk of serious haemorrhage and significant elevations in INR and<br />prothrombin time when clarithromycin is co-administered with warfarin. INR and<br />prothrombin times should be frequently monitored while patients are receiving<br />clarithromycin and oral anticoagulants concurrently (see section 4.4 and 4.5).<br />There have been rare reports of clarithromycin ER tablets in the stool, many of which<br />have occurred in patients with anatomic (including ileostomy or colostomy) or<br />functional gastrointestinal disorders with shortened GI transit times. In several<br />reports, tablet residues have occurred in the context of diarrhoea. It is recommended<br />that patients who experience tablet residue in the stool and no improvement in their<br />condition should be switched to a different clarithromycin formulation (e.g.<br />suspension) or another antibiotic.<br />Special population: Adverse Reactions in Immunocompromised Patients (see section<br />e)</p><p>d. Paediatric populations<br />Clinical trials have been conducted using clarithromycin paediatric suspension in<br />children 6 months to 12 years of age. Therefore, children under 12 years of age<br />should use clarithromycin paediatric suspension. There are insufficient data to<br />recommend a dosage regimen for use of the clarithromycin IV formulation in patients<br />less than 18 years of age.<br />Frequency, type and severity of adverse reactions in children are expected to be the<br />same as in adults.<br />e. Other special populations<br />Immunocompromised patients<br />In AIDS and other immunocompromised patients treated with the higher doses of<br />clarithromycin over long periods of time for mycobacterial infections, it was often<br />difficult to distinguish adverse events possibly associated with clarithromycin<br />administration from underlying signs of Human Immunodeficiency Virus (HIV) disease<br />or intercurrent illness.</p><p>In adult patients, the most frequently reported adverse reactions by patients treated<br />with total daily doses of 1000 mg and 2000mg of clarithromycin were: nausea,<br />vomiting, taste perversion, abdominal pain, diarrhoea, rash, flatulence, headache,<br />constipation, hearing disturbance, Serum Glutamic Oxaloacetic Transaminase<br />(SGOT) and Serum Glutamic Pyruvate Transaminase (SGPT) elevations. Additional<br />low-frequency events included dyspnoea, insomnia and dry mouth. The incidences<br />were comparable for patients treated with 1000mg and 2000mg, but were generally<br />about 3 to 4 times as frequent for those patients who received total daily doses of<br />4000mg of clarithromycin.<br />In these immunocompromised patients, evaluations of laboratory values were made<br />by analysing those values outside the seriously abnormal level (i.e. the extreme high<br />or low limit) for the specified test. On the basis of these criteria, about 2% to 3% of<br />those patients who received 1000mg or 2000mg of clarithromycin daily had seriously<br />abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell<br />and platelet counts. A lower percentage of patients in these two dosage groups also<br />had elevated Blood Urea Nitrogen levels. Slightly higher incidences of abnormal<br />values were noted for patients who received 4000mg daily for all parameters except<br />White Blood Cell.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin can be<br />expected to produce gastro-intestinal symptoms. One patient who had a history of<br />bipolar disorder ingested 8 grams of clarithromycin and showed altered mental<br />status, paranoid behaviour, hypokalemia and hypoxemia. Adverse reactions<br />accompanying overdose should be treated by the prompt elimination of unabsorbed<br />drug and supportive measures. As with other macrolides, clarithromycin serum<br />levels are not expected to be appreciably affected by haemodialysis or peritoneal<br />dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamics properties:<br />Pharmacotherapeutic Group: Macrolides, ATC Code: J01FA09<br />Mode of action<br />Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its<br />antibacterial action by binding to the 50s ribosomal sub-unit of susceptible bacteria<br />and suppresses protein synthesis. It is highly potent against a wide variety of aerobic<br />and anaerobic gram-positive and gram-negative organisms. The minimum inhibitory<br />concentrations (MICs) of clarithromycin are generally two-fold lower than the MICs of<br />erythromycin.<br />The 14-hydroxy metabolite of clarithromycin also has antimicrobial activity. The MICs<br />of this metabolite are equal or two-fold higher than the MICs of the parent compound,</p><p>except for H. influenzae where the 14-hydroxy metabolite is two-fold more active than<br />the parent compound.<br />Clarithromycin is usually active against the following organisms in vitro:-<br />Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible);<br />Streptococcus pyogenes (Group A beta-hemolytic streptococci); alpha-hemolytic<br />streptococci (viridans group); Streptococcus (Diplococcus)pneumoniae;<br />Streptococcus agalactiae; Listeria monocytogenes.<br />Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae;<br />Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila;<br />Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.<br />Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.<br />Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium<br />leprae;<br />Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens;<br />Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.<br />Clarithromycin has bactericidal activity against several bacterial strains. The<br />organisms include Haemophilus influenzae, Streptococcus pneumoniae,<br />Streptococcus pyogenes, Streptococcus agalactiae, Moraxella (Branhamella)<br />catarrhalis, Neisseria gonorrhoeae, H. pylori and Campylobacter spp.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>H. pylori is associated with acid peptic disease including duodenal ulcer and gastric<br />ulcer in which about 95% and 80% of patients respectively are infected with the<br />agent. H. pylori is also implicated as a major contribution factor in the development of<br />gastric and ulcer recurrence in such patients.<br />Clarithromycin has been used in small numbers of patients in other treatment<br />regimens. Possible kinetic interactions have not been fully investigated. These<br />regimens include:<br />Clarithromycin plus tinidazole and omeprazole; clarithromycin plus tetracycline,<br />bismuth subsalicylate and ranitidine; clarithromycin plus ranitidine alone.<br />Clinical studies using various different H. pylori eradication regimens have shown that<br />eradication of H. pylori prevents ulcer recurrence.<br />Clarithromycin is rapidly and well absorbed from the gastro-intestinal tract after oral<br />administration of Clarithromycin tablets. The microbiologically active metabolite 14-</p><p>hydroxyclarithromycin is formed by first pass metabolism. Clarithromycin may be<br />given without regard to meals as food does not affect the extent of bioavailability of<br />Clarithromycin tablets. Food does slightly delay the onset of absorption of<br />clarithromycin and formation of the 14-hydroxymetabolite. The pharmacokinetics of<br />clarithromycin are non linear; however, steady-state is attained within 2 days of<br />dosing. At 250 mg b.i.d. 15-20% of unchanged drug is excreted in the urine. With 500<br />mg b.i.d. daily dosing urinary excretion is greater (approximately 36%). The 14-<br />hydroxyclarithromycin is the major urinary metabolite and accounts for 10-15% of the<br />dose. Most of the remainder of the dose is eliminated in the faeces, primarily via the<br />bile. 5-10% of the parent drug is recovered from the faeces.<br />When clarithromycin 500 mg is given three times daily, the clarithromycin plasma<br />concentrations are increased with respect to the 500 mg twice daily dosage.<br />Clarithromycin provides tissue concentrations that are several times higher than the<br />circulating drug levels. Increased levels have been found in both tonsillar and lung<br />tissue. Clarithromycin is 80% bound to plasma proteins at therapeutic levels.<br />Clarithromycin also penetrates the gastric mucus. Levels of clarithromycin in gastric<br />mucus and gastric tissue are higher when clarithromycin is co-administered with<br />omeprazole than when clarithromycin is administered alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In acute mouse and rat studies, the median lethal dose was greater than the highest<br />feasible dose for administration (5g/kg).<br />In repeated dose studies, toxicity was related to dose, duration of treatment and<br />species. Dogs were more sensitive than primates or rats. The major clinical signs at<br />toxic doses included emesis, weakness, reduced food consumption and weight gain,<br />salivation, dehydration and hyperactivity. In all species the liver was the primary<br />target organ at toxic doses. Hepatotoxicity was detectable by early elevations of liver<br />function tests. Discontinuation of the drug generally resulted in a return to or toward<br />normal results. Other tissues less commonly affected included the stomach, thymus<br />and other lymphoid tissues and the kidneys. At near therapeutic doses, conjunctival<br />injection and lacrimation occurred only in dogs. At a massive dose of 400mg/kg/day,<br />some dogs and monkeys developed corneal opacities and/or oedema.<br />Fertility and reproduction studies in rats have shown no adverse effects.<br />Teratogenicity studies in rats (Wistar (p.o.) and Spraque-Dawley (p.o. and i.v.)), New<br />Zealand White rabbits and cynomolgous monkeys failed to demonstrate any<br />teratogenicity from clarithromycin. However, a further similar study in Sprague-<br />Dawley rats indicated a low (6%) incidence of cardiovascular abnormalities, which<br />appeared to be due to spontaneous expression of genetic changes. Two mouse<br />studies revealed a variable incidence (3-30%) of cleft palate and embryonic loss was<br />seen in monkeys but only at dose levels, which were clearly toxic to the mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Klare 500 mg film-coated tablets contain the following excipients<br />Material Name : Qty/unit (mg/ Tablet)<br />Tablet core:<br />Croscarmellose Sodium 70.00<br />Microcrystalline Cellulose 170.60<br />Povidone K 30 40.00<br />Pregelatinized Maize Starch 130.00<br />Colloidal Anhydrous Silica 14.40<br />Talc Powder 35.00<br />Stearic Acid 25.00<br />Magnesium Stearate 15.00<br />Tablet coating:<br />Opadry OYS-32924 Yellow 30.00</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The shelf life is 2 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />This medicinal product does not require any special storage conditions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-The immediate packaging material is PVC/PVDC/Alu Blister.<br />-Pack size: 14 Film-Coated Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MEDICO (Middle East Distribution Co.Ltd.)
Riyadh, KSA
Tel: +966(011)2653948
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>